ASH 2017 | Targeted Antibody Mogamulizumab Superior to Vorinostat for Previously Treated CTCL

In a large, international, randomized Phase III trial, patients with previously treated cutaneous T-cell lymphoma (CTCL) who received the investigational targeted drug mogamulizumab had significantly better progression-free survival, response rate, and quality of life than patients who received vorinostat, a U.S. Food and Drug Administration (FDA)-approved standard-of-care treatment for patients with CTCL. The adverse events observed with mogamulizumab treatment were generally mild to moderate in severity.

The primary endpoint was progression-free survival — the time elapsed until the cancer began to show signs of getting worse — or death for any reason. Among 372 patients included in the trial, the median progression-free survival was 7.7 months for patients treated with mogamulizumab, compared with 3.1 months for those treated with vorinostat, reported lead study author Youn H. Kim, MD, professor of dermatology and director of the Multidisciplinary Cutaneous Lymphoma Program at the Stanford University School of Medicine.

“We found that mogamulizumab has convincing clinical activity, not just in skin, but also in clearing malignant T-cells in the blood and lymph nodes,” said Dr. Kim. “Progression-free survival and overall global response outcomes are clearly superior, the side effects are tolerable, and we see measurable improvements in quality of life with mogamulizumab compared with vorinostat. Taken together, these findings represent a durable and clinically meaningful benefit for patients with CTCL.”

This session was recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.